A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT00139282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older in the Western world. AMD presents in two different types: "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will evaluate the safety and efficacy of Squalamine lactate in the treatment of AMD in patients, the exact number of which will be determined based on data from the sponsor's ongoing Phase 2 trials. The trial objective is to evaluate the safety and efficacy of two doses of Squalamine lactate for Injection administered as intravenous infusions weekly for 4 weeks followed by maintenance doses every 4 weeks through week 104 compared with the safety and efficacy in the control group.
Study identification
- NCT ID
- NCT00139282
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Nov 27, 2007
Started 2005
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Eldorado Retina Associates | Louisville | Colorado | 80027 | — |
| Florida Eye Microsurgical Institute | Boynton Beach | Florida | 33426 | — |
| National Ophthalmic Research Institute | Fort Myers | Florida | 33912 | — |
| University of Florida | Jacksonville | Florida | 32256 | — |
| Magruder Eye Institute | Orlando | Florida | 32803 | — |
| East Florida Eye Institute | Stuart | Florida | 34994 | — |
| Retina Associates of Florida | Tampa | Florida | 33609 | — |
| Center for Retina and Macular Disease | Winter Haven | Florida | 33880 | — |
| Midwest Eye Institute | Indianapolis | Indiana | 46280 | — |
| Retina Associates, PA | Shawnee Mission | Kansas | 66204 | — |
| Cumberland Valley Retina Consultants, PC | Hagerstown | Maryland | 21740 | — |
| Delaware Valley Retina Associates | Lawrenceville | New Jersey | 08648 | — |
| Retina Associates of New Jersey | Teaneck | New Jersey | 07666 | — |
| MaculaCare | New York | New York | 10021 | — |
| Charlotte Eye, Ear, Nose & Throat Associates | Charlotte | North Carolina | 28210 | — |
| Horizon Eye Care | Charlotte | North Carolina | 28211 | — |
| The Ohio State University, Havener Eye Institute | Columbus | Ohio | 43210 | — |
| Penn State Ophthalmology | Hershey | Pennsylvania | 17033 | — |
| Retina Vitreous Consultants | Pittsburgh | Pennsylvania | 15213 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Genaera Corporation | Plymouth Meeting | Pennsylvania | 19462 | — |
| Carolina Retina Center | Columbia | South Carolina | 29223 | — |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 57701 | — |
| Southeastern Retina Associates | Kingsport | Tennessee | 37660 | — |
| Retina Research Center | Austin | Texas | 78705 | — |
| Garcia & Associates, MD, PA | Houston | Texas | 77002 | — |
| John Moran Eye Center | Salt Lake City | Utah | 84132 | — |
| Virginia Retina Center | Leesburg | Virginia | 20176 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00139282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 27, 2007 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00139282 live on ClinicalTrials.gov.